Drug resistance is the main reason for antiretroviral treatment (ART) failure. Information on the prevalence of pediatric HIV drug resistance (HIVDR) in Vietnam is important to assist in the determination of the optimal ART regimen. We enrolled a prospective cohort of children newly initiating ART at one of two main pediatric hospitals in Ho Chi Minh City from December 2011 to March 2014. Demographic and clinical data were collected at baseline and supplemented by genotyping and VL at start and after 12 months or when first-line ART ends if it comes first. Of 136 patients enrolled, the mean age was 4.7 years; 17 (12%) exposed to ARV to prevent maternal to child HIV transmission; seven (5.15%) carried at least one strain of HIV with mutations related to ARV resistance, two (1.47%) against Nucleotide Reverse Transcriptase Inhibitors (NRTIs) (AZT, D4T), one (0.74%) against Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs) (NVP), and four (2.94%) against Nelfinavir of Protease Inhibitors (PIs). At 12 months, 121 (89%) children were still receiving the first line ART, 7 (5%) died and 8 (6%) were lost to follow-up. Among 121 children on ART, 107(88%) achieved VL suppression (\<1,000 copies/mL); 9 (7%) had acquired HIVDR mutations, three against NRTIs only, and six (4.96%) against both NRTIs and NNRTIs. The most prevalent mutation was the M184V (4.96%, *n* = 6) causing high-level resistance to 3TC, FTC and low-level resistance to ddI and ABC. Some TAMs were also found (D67N, K70R, T215F, K219Q). No major resistance mutations to PIs were detected. Viral load at initiation is associated with HIVDR at 12 months. Low levels of virologic failure and HIVDR were observed in pediatric patients. However, since some multidrug-resistant or cross-resistant mutations were recorded, continued monitoring of HIV drug-resistance in pediatric patients is needed.
